FY2024 Earnings Forecast for BioAtla Issued By HC Wainwright

by · The Cerbat Gem

BioAtla, Inc. (NASDAQ:BCAB – Free Report) – Investment analysts at HC Wainwright issued their FY2024 earnings estimates for BioAtla in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($1.46) for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for BioAtla’s Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

BioAtla (NASDAQ:BCAB – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12. The business had revenue of $11.00 million for the quarter. During the same quarter in the previous year, the business earned ($0.70) EPS.

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a research note on Monday, September 16th.

View Our Latest Stock Report on BioAtla

BioAtla Trading Down 14.1 %

BioAtla stock opened at $1.71 on Friday. BioAtla has a twelve month low of $1.14 and a twelve month high of $4.02. The firm has a market capitalization of $82.66 million, a P/E ratio of -1.01 and a beta of 1.03. The stock’s fifty day simple moving average is $1.92 and its 200-day simple moving average is $1.88.

Hedge Funds Weigh In On BioAtla

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in shares of BioAtla during the second quarter worth about $872,000. Scion Asset Management LLC purchased a new stake in BioAtla in the second quarter valued at approximately $869,000. GSA Capital Partners LLP acquired a new stake in shares of BioAtla in the third quarter valued at approximately $623,000. Bank of Montreal Can increased its holdings in shares of BioAtla by 55.1% in the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock valued at $554,000 after acquiring an additional 143,521 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in BioAtla by 28.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company’s stock worth $458,000 after purchasing an additional 73,598 shares during the period. 77.23% of the stock is owned by institutional investors and hedge funds.

BioAtla Company Profile

(Get Free Report)

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.

Further Reading